JP6925969B2 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP6925969B2
JP6925969B2 JP2017541780A JP2017541780A JP6925969B2 JP 6925969 B2 JP6925969 B2 JP 6925969B2 JP 2017541780 A JP2017541780 A JP 2017541780A JP 2017541780 A JP2017541780 A JP 2017541780A JP 6925969 B2 JP6925969 B2 JP 6925969B2
Authority
JP
Japan
Prior art keywords
pth
composition
snac
protease inhibitor
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017541780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504444A5 (ja
JP2018504444A (ja
Inventor
グレゴリー バーシュテイン
グレゴリー バーシュテイン
アリエル ロスナー
アリエル ロスナー
フィリップ エム シュワルツ
フィリップ エム シュワルツ
ヒレル ガリッツァー
ヒレル ガリッツァー
Original Assignee
エンテラ バイオ エルティーディー．
エンテラ バイオ エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56614456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6925969(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エンテラ バイオ エルティーディー．, エンテラ バイオ エルティーディー． filed Critical エンテラ バイオ エルティーディー．
Publication of JP2018504444A publication Critical patent/JP2018504444A/ja
Publication of JP2018504444A5 publication Critical patent/JP2018504444A5/ja
Priority to JP2021128281A priority Critical patent/JP7275207B2/ja
Application granted granted Critical
Publication of JP6925969B2 publication Critical patent/JP6925969B2/ja
Priority to JP2023015960A priority patent/JP7775239B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
JP2017541780A 2015-02-09 2016-02-09 医薬組成物 Active JP6925969B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021128281A JP7275207B2 (ja) 2015-02-09 2021-08-04 骨粗鬆症の治療
JP2023015960A JP7775239B2 (ja) 2015-02-09 2023-02-06 骨粗鬆症の治療

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201562113600P 2015-02-09 2015-02-09
US201562113625P 2015-02-09 2015-02-09
US201562113673P 2015-02-09 2015-02-09
US201562113638P 2015-02-09 2015-02-09
US201562113619P 2015-02-09 2015-02-09
US201562113604P 2015-02-09 2015-02-09
US201562113629P 2015-02-09 2015-02-09
US62/113,638 2015-02-09
US62/113,625 2015-02-09
US62/113,619 2015-02-09
US62/113,600 2015-02-09
US62/113,629 2015-02-09
US62/113,604 2015-02-09
US62/113,673 2015-02-09
PCT/IL2016/050154 WO2016128973A1 (en) 2015-02-09 2016-02-09 Treatment of osteoporosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021128281A Division JP7275207B2 (ja) 2015-02-09 2021-08-04 骨粗鬆症の治療

Publications (3)

Publication Number Publication Date
JP2018504444A JP2018504444A (ja) 2018-02-15
JP2018504444A5 JP2018504444A5 (ja) 2019-03-14
JP6925969B2 true JP6925969B2 (ja) 2021-08-25

Family

ID=56614456

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2017541780A Active JP6925969B2 (ja) 2015-02-09 2016-02-09 医薬組成物
JP2017541786A Active JP6925970B2 (ja) 2015-02-09 2016-02-09 副甲状腺機能低下症の治療
JP2021128281A Active JP7275207B2 (ja) 2015-02-09 2021-08-04 骨粗鬆症の治療
JP2021128296A Pending JP2021176914A (ja) 2015-02-09 2021-08-04 副甲状腺機能低下症の治療
JP2023015960A Active JP7775239B2 (ja) 2015-02-09 2023-02-06 骨粗鬆症の治療
JP2023078011A Pending JP2023100920A (ja) 2015-02-09 2023-05-10 副甲状腺機能低下症の治療

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017541786A Active JP6925970B2 (ja) 2015-02-09 2016-02-09 副甲状腺機能低下症の治療
JP2021128281A Active JP7275207B2 (ja) 2015-02-09 2021-08-04 骨粗鬆症の治療
JP2021128296A Pending JP2021176914A (ja) 2015-02-09 2021-08-04 副甲状腺機能低下症の治療
JP2023015960A Active JP7775239B2 (ja) 2015-02-09 2023-02-06 骨粗鬆症の治療
JP2023078011A Pending JP2023100920A (ja) 2015-02-09 2023-05-10 副甲状腺機能低下症の治療

Country Status (9)

Country Link
US (8) US10583177B2 (enExample)
EP (5) EP3256113B1 (enExample)
JP (6) JP6925969B2 (enExample)
CN (5) CN114949185A (enExample)
CA (3) CA3011654A1 (enExample)
HK (5) HK1247822A1 (enExample)
IL (7) IL283258B2 (enExample)
MX (2) MX2017010220A (enExample)
WO (5) WO2016128972A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6925969B2 (ja) * 2015-02-09 2021-08-25 エンテラ バイオ エルティーディー． 医薬組成物
SG11201901070YA (en) * 2016-08-17 2019-03-28 Entera Bio Ltd Formulations for oral administration of active agents
WO2019149880A1 (en) * 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2020183318A1 (en) * 2019-03-08 2020-09-17 Anya Biopharm Inc. Oral formulation and treatment of pth analog.
AU2020342512A1 (en) * 2019-09-03 2022-03-31 Amgen Inc. IL-22 oral, intra-rectal, or other gut-related compositions and methods of use thereof
CN114306249A (zh) * 2020-09-28 2022-04-12 深圳翰宇药业股份有限公司 一种特立帕肽冻干药物组合物及其制备方法
US12251208B2 (en) * 2020-11-30 2025-03-18 International Business Machines Corporation Time controlled medication
CN114288388B (zh) * 2022-01-25 2023-11-03 华中科技大学同济医学院附属协和医院 网膜素在制备炎症性肠病治疗药物中的应用
WO2023161935A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone
WO2023161938A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide
AU2023226619A1 (en) * 2022-02-24 2024-10-03 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-1 and analogs thereof
KR20240145523A (ko) * 2022-02-24 2024-10-07 엔테라 바이오 리미티드 글루카곤 유사 펩타이드-2의 경구 투여를 위한 산 중화 중합체를 포함하는 제형
WO2023161936A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
MX2024010387A (es) * 2022-02-24 2024-09-04 Entera Bio Ltd Formulaciones que comprenden polimero neutralizante de acido para administracion oral de agentes activos.
US20250186559A1 (en) * 2022-02-24 2025-06-12 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents
WO2025046590A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations for oral administration of active agents
CN121398805A (zh) * 2024-01-05 2026-01-23 成都国为生物医药有限公司 一种地非法林的口服药物组合物
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance
US20260077020A1 (en) * 2025-09-26 2026-03-19 Danielle Marie Le Roux Oral peptide pharmaceutical composition that facilitates enhanced oral absorption

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360793A (en) * 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
CN1162917A (zh) * 1994-10-07 1997-10-22 伯温德药品服务公司 肠内涂层组合物，用其涂覆的方法和涂覆制品
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2220301C (en) * 1995-06-02 2006-02-21 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
JP3880093B2 (ja) 1995-08-08 2007-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
CN1228708A (zh) * 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
SK151599A3 (en) 1997-05-14 2000-09-12 Rhone Poulenc Rorer Pharma Peptide parathyroid hormone analogs
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
WO2000048589A1 (en) * 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
WO2000050386A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
HK1048801B (en) 1999-11-05 2009-08-28 Emisphere Technologies, Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
PT1616561E (pt) * 1999-12-28 2008-07-09 Ajinomoto Kk Preparação antidiabética para administração oral
MXPA04001418A (es) * 2001-08-17 2004-05-27 Novartis Ag Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides.
JP4602668B2 (ja) 2001-11-13 2010-12-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するためのフェノキシアミン化合物および組成物
JP5196701B2 (ja) * 2001-11-29 2013-05-15 エミスフィアー テクノロジーズ インコーポレイテッド クロモリンナトリウムの経口投与用製剤
JP4417110B2 (ja) 2001-12-19 2010-02-17 株式会社三和化学研究所 放出制御型成型品
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
AR040737A1 (es) * 2002-08-01 2005-04-20 Novartis Ag Administracion oral de calcitonina
CA2531136A1 (en) 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
JP2005281231A (ja) 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口ｄｄｓ製剤
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP2006111558A (ja) 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
NZ555244A (en) 2004-11-19 2010-06-25 Smithkline Beecham Corp Manufacture process for pharmaceutical product allowing delivery of a plurality of active agents
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US20080153779A1 (en) 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JP5123471B2 (ja) 2005-08-18 2013-01-23 帝人ファーマ株式会社 用量調整が容易な製剤
AU2006288703B2 (en) 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
CN101309674A (zh) 2005-11-17 2008-11-19 诺瓦提斯公司 药物组合物
US20070178155A1 (en) * 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
WO2007117706A2 (en) 2006-04-07 2007-10-18 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2007372B1 (en) 2006-04-18 2015-03-04 Emisphere Technologies, Inc. Dialkyl ether delivery agents
KR101428826B1 (ko) * 2006-12-12 2014-08-08 가부시키가이샤 호리바 에스텍 유량 비율 제어 장치
EP2061440A2 (en) 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
WO2008132727A2 (en) * 2007-04-26 2008-11-06 Technion Research And Development Foundation Ltd Oral delivery of proteins and peptides
EP2200592A2 (en) * 2007-09-11 2010-06-30 Orahealth Corporation Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach
WO2009080764A2 (en) 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
IT1393244B1 (it) 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
BR112012026098A2 (pt) * 2010-04-16 2016-11-22 Novartis Ag métodos e composições para melhorar a osseointegração de implante.
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
US20130224300A1 (en) 2011-08-26 2013-08-29 Edward T. Maggio Compositions and methods thereof for oral administration of drugs
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
JP6517690B2 (ja) * 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
JP6925969B2 (ja) 2015-02-09 2021-08-25 エンテラ バイオ エルティーディー． 医薬組成物
SG11201901070YA (en) 2016-08-17 2019-03-28 Entera Bio Ltd Formulations for oral administration of active agents
JP7419862B2 (ja) 2020-02-14 2024-01-23 株式会社リコー 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置

Also Published As

Publication number Publication date
US20180021272A1 (en) 2018-01-25
EP3256113A4 (en) 2018-11-14
HK1247823A1 (zh) 2018-10-05
IL253803B (en) 2021-06-30
MX2017010220A (es) 2018-02-21
WO2016128974A1 (en) 2016-08-18
EP3256114A4 (en) 2018-11-21
CA3011657A1 (en) 2016-08-18
US20240398904A1 (en) 2024-12-05
IL283258A (en) 2021-07-29
BR112017017112A2 (en) 2018-04-03
JP6925970B2 (ja) 2021-08-25
JP2023055902A (ja) 2023-04-18
JP2018504445A (ja) 2018-02-15
EP3256152A1 (en) 2017-12-20
IL253802A0 (en) 2017-09-28
MX2022014313A (es) 2022-12-07
JP2018504444A (ja) 2018-02-15
CN114949185A (zh) 2022-08-30
JP2021176914A (ja) 2021-11-11
HK1247838A1 (zh) 2018-10-05
CA2975710A1 (en) 2016-08-18
EP3256152A4 (en) 2018-11-14
JP2023100920A (ja) 2023-07-19
CN113694190B (zh) 2024-05-07
IL292218A (en) 2022-06-01
EP3256153A1 (en) 2017-12-20
US20180028622A1 (en) 2018-02-01
EP3256149A4 (en) 2019-08-14
CN113713090B (zh) 2023-06-02
US20200138913A1 (en) 2020-05-07
WO2016128971A1 (en) 2016-08-18
EP3256113B1 (en) 2025-04-02
WO2016128970A1 (en) 2016-08-18
WO2016128972A1 (en) 2016-08-18
CA2975578A1 (en) 2016-08-18
IL253804A0 (en) 2017-09-28
US20180036382A1 (en) 2018-02-08
IL283258B1 (en) 2023-07-01
JP2021176913A (ja) 2021-11-11
JP7275207B2 (ja) 2023-05-17
US20180036234A1 (en) 2018-02-08
WO2016128973A1 (en) 2016-08-18
HK1247822A1 (zh) 2018-10-05
CA2975676A1 (en) 2016-08-18
CN113713090A (zh) 2021-11-30
US10583177B2 (en) 2020-03-10
HK1247835A1 (zh) 2018-10-05
IL292417B1 (en) 2024-08-01
CN113730556A (zh) 2021-12-03
US20240181020A1 (en) 2024-06-06
CN113694190A (zh) 2021-11-26
EP3256114A1 (en) 2017-12-20
IL253802B (en) 2022-06-01
US12076373B2 (en) 2024-09-03
HK1247843A1 (zh) 2018-10-05
CA3011654A1 (en) 2016-08-18
IL292218B1 (en) 2024-06-01
IL292218B2 (en) 2024-10-01
EP3256113A1 (en) 2017-12-20
CA2975710C (en) 2023-08-08
CN107427481A (zh) 2017-12-01
EP3256149A1 (en) 2017-12-20
EP3256153A4 (en) 2018-11-21
US20180050096A1 (en) 2018-02-22
IL292417A (en) 2022-06-01
IL303216A (en) 2023-07-01
IL292417B2 (en) 2024-12-01
IL253803A0 (en) 2017-09-28
IL283258B2 (en) 2023-11-01
IL253804B (en) 2022-05-01
JP7775239B2 (ja) 2025-11-25

Similar Documents

Publication Publication Date Title
JP7775239B2 (ja) 骨粗鬆症の治療
JP7736834B2 (ja) 活性薬剤の経口投与のための製剤
HK40064924B (en) Treatment of osteoporosis
HK40078392A (en) Treatment of osteoporosis
HK40064568A (en) Treatment of osteoporosis
HK40064572A (en) Treatment of osteoporosis
HK40064924A (en) Treatment of osteoporosis
HK40064568B (zh) 骨质疏松症的治疗
CA2975578C (en) Treatment of hypoparathyroidism
BR122024010024A2 (pt) Forma de dosagem multiunitária de composição farmacêutica, uso de uma forma de dosagem multiunitária de composição farmacêutica, uso de uma forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária, e, kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171019

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190131

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190710

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210804

R150 Certificate of patent or registration of utility model

Ref document number: 6925969

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250